We are live on ! Find out more
NMTC icon

NeuroOne Medical Technologies

7 hedge funds and large institutions have $989K invested in NeuroOne Medical Technologies in 2021 Q3 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

133% more funds holding

Funds holding: 37 (+4)

0.22% less ownership

Funds ownership: 0.57%0.35% (-0.22%)

64% less capital invested

Capital invested by funds: $2.73M → $989K (-$1.74M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
7
Holders Change
+4
Holders Change %
+133.33%
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
6
Increased
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change

NMTC Hedge Fund Activity: Q3 2021 in Review

7 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q3 2021, worth a combined $989K — down 64% from $2.73M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new NMTC positions and 1 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $508K. The largest seller was Baker Avenue Asset Management, exiting entirely with an estimated $1.19M sold.

  • 7 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q3 2021, up from 3 in Q2 2021.
  • Funds reported $989K of NeuroOne Medical Technologies stock for Q3 2021, down 64% quarter-over-quarter.
  • 6 funds opened new NeuroOne Medical Technologies positions in Q3 2021 and 1 closed out, a net change of +5 holders.
  • The largest NeuroOne Medical Technologies buyer in Q3 2021 was Millennium Management, an estimated $508K added.
  • The largest NeuroOne Medical Technologies seller in Q3 2021 was Baker Avenue Asset Management, an estimated $1.19M sold.

Based on aggregated 13F filings for Q3 2021.